| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 刘浩 | 华创证券 | 医药生物 | 72.76% | 72.76% | 21.71% | 29.41% | 2 | -47.33% | 2025-07-01 |
| 2 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 72.76% | 62.34% | 43.46% | 12.50% | 6 | -27.10% | 2025-06-05 |
| 3 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 72.66% | 79.33% | 41.53% | 12.50% | 7 | -27.10% | 2025-07-09 |
| 4 | 刘浩 | 华创证券 | 医药生物 | 72.64% | 73.02% | 16.85% | 29.41% | 2 | -47.33% | 2025-07-14 |
| 5 | 阳景 | 浦银国际证券 | 医药生物 | 72.38% | 42.25% | 29.83% | 100.00% | 4 | 0.00% | 2025-09-09 |
| 6 | 唐寅灏 | 中信证券 | 医药生物 | 72.18% | 53.66% | 13.65% | 85.71% | 13 | -8.47% | 2025-09-16 |
| 7 | 唐寅灏 | 中信证券 | 医药生物 | 72.09% | 76.71% | 42.82% | 85.71% | 13 | -8.47% | 2025-08-12 |
| 8 | 刘浩 | 华创证券 | 医药生物 | 72.04% | 59.80% | 41.45% | 29.41% | 2 | -47.33% | 2025-06-09 |
| 9 | 唐寅灏 | 中信证券 | 医药生物 | 71.94% | 74.99% | 37.56% | 85.71% | 13 | -8.47% | 2025-08-08 |
| 10 | 唐寅灏 | 中信证券 | 医药生物 | 71.88% | 55.73% | 21.03% | 85.71% | 13 | -8.47% | 2025-09-24 |
| 11 | 唐寅灏 | 中信证券 | 医药生物 | 71.86% | 53.21% | 23.52% | 85.71% | 13 | -8.47% | 2025-09-22 |
| 12 | 阳景 | 浦银国际证券 | 医药生物 | 71.32% | 44.52% | 35.00% | 100.00% | 3 | 0.00% | 2025-08-25 |
| 13 | 顾资然 | 中信证券 | 医药生物 | 71.19% | 61.06% | 55.37% | 66.67% | 6 | -1.79% | 2025-08-21 |
| 14 | 李安飞 | 广发证券 | 医药生物 | 71.06% | 58.17% | 47.02% | -2.86% | 1 | -56.96% | 2025-06-12 |
| 15 | 阳景 | 浦银国际证券 | 医药生物 | 71.00% | 46.07% | 28.40% | 100.00% | 4 | 0.00% | 2025-09-11 |
| 16 | 刘浩 | 华创证券 | 医药生物 | 70.98% | 64.74% | 42.31% | 29.41% | 2 | -47.33% | 2025-06-16 |
| 17 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 70.88% | 76.59% | 25.90% | 12.50% | 7 | -27.10% | 2025-07-04 |
| 18 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 70.68% | 76.38% | 25.75% | 12.50% | 7 | -27.10% | 2025-07-03 |
| 19 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 70.53% | 66.13% | 50.59% | 12.50% | 6 | -27.10% | 2025-05-30 |
| 20 | 唐寅灏 | 中信证券 | 医药生物 | 70.46% | 52.22% | 18.58% | 85.71% | 13 | -8.47% | 2025-09-17 |